Vise Technologies Inc. Takes $1.43 Million Position in Biogen Inc. $BIIB

Vise Technologies Inc. bought a new stake in Biogen Inc. (NASDAQ:BIIB) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 6,627 shares of the biotechnology company’s stock, valued at approximately $1,432,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BIIB. BlackRock Inc. acquired a new position in Biogen during the 2nd quarter worth approximately $3,453,878,000. Orbimed Advisors LLC purchased a new stake in shares of Biogen during the 1st quarter worth $11,293,000. LSV Asset Management lifted its position in shares of Biogen by 3.3% during the 4th quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock worth $55,756,000 after purchasing an additional 9,976 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new position in shares of Biogen during the fourth quarter worth $2,006,000. Finally, Systematic Financial Management LP increased its holdings in Biogen by 256.3% in the fourth quarter. Systematic Financial Management LP now owns 16,640 shares of the biotechnology company’s stock valued at $2,928,000 after buying an additional 11,970 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BIIB. Rothschild & Co Redburn raised their price target on Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Mizuho boosted their target price on Biogen from $221.00 to $241.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. TD Cowen increased their price target on shares of Biogen from $215.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Needham & Company LLC increased their price target on shares of Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Zacks Research upgraded shares of Biogen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $227.07.

Biogen Stock Up 1.1%

BIIB stock opened at $216.78 on Friday. Biogen Inc. has a one year low of $131.52 and a one year high of $222.15. The company has a fifty day moving average of $205.53 and a 200-day moving average of $194.48. The stock has a market capitalization of $32.03 billion, a PE ratio of 38.37, a price-to-earnings-growth ratio of 6.75 and a beta of 0.17. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the prior year, the company posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, analysts expect that Biogen Inc. will post 12.39 EPS for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.